Immunoassay utilizing trapping conjugate

Inventors

Esfandiari, Javanbakhsh

Assignees

Chembio Diagnostic Systems Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10473655-B2

Patent

Publication Date

2019-11-12

Expiration Date


Abstract

Test devices are provided for determining the presence of a first ligand in a sample. In some embodiments depletion conjugates are used to deplete the ligands different from but related to the first ligands from the sample. In some embodiments, interim binding agents are used to enhance the test signal.

Core Innovation

The disclosed invention relates to a test device for determining the presence of a first ligand in a liquid sample. The device includes a first sorbent strip with a first migration path and a marker conjugate located on or in and adapted to move along the first migration path, the marker conjugate having a first interim binding agent of a first pair adapted to bind to a second interim binding agent of the first pair.

The device further includes a second sorbent strip distinct from the first sorbent strip, with a second location for receiving the liquid sample and defining a second migration path. The second migration path includes first molecules that include a first-ligand-binding molecule and a first interim binding agent of a second pair. A second conjugate located on or in and adapted to move along the second migration path includes particles having bound thereto a second interim binding agent of the second pair and a second interim binding agent of the first pair.

A test site is located on or in at least one of the first sorbent strip and the second sorbent strip, with an immobilized first-ligand-binding mechanism for the first ligand. The first and second sorbent strips touch at the test site location, while the second location is removed from the test site so the liquid sample requires time to migrate to the test site and does not immediately wet the test site.

The disclosed examples describe dual-path lateral flow/immunoassay concepts that use related-but-non-target ligands being depleted using a second-ligand binding trapping/depleting conjugate, followed by delivery of a marker conjugate to an immobilized ligand-binding test line. The examples further describe interim binding-agent bridging pairs for binding, including biotin/streptavidin and anti-FITC/FITC antigen, and marker conjugates including gold sol or colored latex, with white latex to reduce visual interference.

Claims Coverage

Independent claim 1 defines a dual-path test device with two distinct sorbent strips, a delayed wetting relationship between the sample-receiving location and the test site, and marker and conjugate components carrying interim binding agent pairs that support binding at an immobilized test site. Dependent claims further refine specific interim binding agent pairs and conjugate particle types, and narrow the detection scheme to HIV p24.

Two distinct sorbent strips with separate migration paths

A first sorbent strip defines a first migration path and a second sorbent strip distinct from the first defines a second migration path for receiving the liquid sample.

Marker conjugate with interim binding agent bridging at the test site

A marker conjugate located on or in and adapted to move along the first migration path, the marker conjugate having a first interim binding agent of a first pair adapted to bind to a second interim binding agent of said first pair.

Second molecules and second conjugate with interim binding agent pairs

First molecules located on or in and adapted to move along the second migration path including a first-ligand-binding molecule and a first interim binding agent of a second pair; and a second conjugate including particles having bound thereto a second interim binding agent of the second pair and a second interim binding agent of the first pair.

Immobilized ligand-binding test site with delayed wetting

A test site located on or in at least one of the first sorbent strip and the second sorbent strip, the test site having an immobilized first-ligand-binding mechanism for said first ligand, wherein the first and second sorbent strips touch at the test site location and the second location is removed from the test site such that liquid applied to the second location requires time to migrate to the test site and does not immediately wet said test site.

Specific interim binding agent pairs

The device defined by specified binding-agent pairs including biotin with streptavidin and anti-FITC antibody with FITC antigen.

White latex particles in the second conjugate

The device where the second conjugate particles include white latex particles.

HIV p24 ligand detection scheme

The device using an HIV p24 ligand as the first ligand, and wherein the second molecules include HIV p24 binding molecules that bind the first ligand.

Claim coverage centers on a dual-path test device with two distinct sorbent strips, where marker and conjugate components carry interim binding agent pairs that enable binding at an immobilized test site, combined with a delayed wetting condition by separating the sample-receiving location from the test site. Dependent refinements specify particular interim binding agent pairs, specify white latex particles, and further narrow the detection scheme to HIV p24.

Stated Advantages

Increased sensitivity.

Non-interference, including test-line vs control behavior described as improved in the examples.

Reduced visual interference by using white latex.

Improved flu detection performance by reducing cross-reactivity between pandemic and seasonal flu-A antibodies as described.

Documented Applications

Detection of influenza targets, including pandemic flu-A versus seasonal cross-reactivity reduction and related flu cross-reactivity handling.

Detection of HIV p24 antigen using interim binding-agent bridging pairs and marker conjugates.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.